The Pill That Could Kill the Cholesterol Needle

The headline result from the CORALreef Lipids trial: enlicitide cut LDL cholesterol by 55.8% versus placebo at 24 weeks. A post-hoc reanalysis (a second look at the data using refined methods) bumped that number to 59.7%. Both were highly statistically significant, and the reductions held steady through a full year of treatment.

In patients with familial hypercholesterolemia, a genetic condition that sends cholesterol levels sky-high from birth, the drug delivered a 59.4% reduction in LDL. The placebo group actually saw their LDL increase by 2.6%. That's a canyon-sized gap.

But enlicitide didn't just lower LDL. It also reduced apolipoprotein B (a protein that carries "bad" cholesterol particles) by 50.3% and lipoprotein(a), another cardiovascular risk marker, by 28.2%. Those secondary wins matter because they suggest the drug attacks heart disease risk from multiple angles.

Perhaps the most impressive stat? Adherence hit 97%. When the treatment is a daily pill instead of a biweekly injection, it turns out people actually take it.

What Wall Street Thinks

Analysts noticed. Stifel called the data "favorable" and noted that enlicitide's performance looks "generally comparable to the injectables." That's the whole ballgame: if a pill can match a needle, the pill wins every time.

BMO Capital Markets took a slightly longer view, pointing to Amgen's recent Repatha data showing a 25% reduction in major adverse cardiovascular events (heart attacks, strokes, cardiovascular death). BMO suggested those results "could set the stage for enlicitide's future readouts," hinting that Merck's cardiovascular outcomes trial, CORALreef Outcomes, will be the real showdown.

That trial has already enrolled over 14,500 patients, and its results will answer the question everyone is waiting on: does enlicitide actually prevent heart attacks and strokes, not just lower a number on a blood test? Lowering LDL is a strong predictor of cardiovascular benefit, but outcomes data is the gold standard regulators and payers demand.

The Safety Question (Spoiler: So Far, So Good)

New drugs always carry a "yeah, but what about side effects?" asterisk. Enlicitide's safety profile so far is surprisingly clean. In the CORALreef trials, adverse events were comparable to placebo, meaning the drug basically looked like a sugar pill from a side-effect standpoint.

That's a big deal. Injectable PCSK9 inhibitors are generally well tolerated, but injection-site reactions and the psychological burden of self-injecting are real barriers. Removing the needle removes those problems entirely.

The $3 Billion Question

Repatha currently dominates the PCSK9 market with a 52.4% revenue share. Novartis is pushing Leqvio (inclisiran), an siRNA therapy that only requires two injections per year, as the "convenient" alternative. But even twice a year is infinity-percent more needles than zero.

Merck's pitch is simple: same efficacy, no needles, once a day. If the cardiovascular outcomes data cooperates, enlicitide could become the default PCSK9 inhibitor for the vast majority of patients. Doctors already prefer prescribing pills over injections when they can. Patients prefer taking them. Insurance companies prefer paying for drugs people actually use.

The competitive implications are significant. Amgen's Repatha and Sanofi's Praluent would face their first serious oral competitor. Novartis would need to argue that two injections a year is meaningfully more convenient than a daily pill (good luck with that). And the numerous other companies developing PCSK9 inhibitors would need to recalibrate their strategies around a new standard of care.

What Comes Next

The CORALreef Outcomes trial is the next catalyst. Hard cardiovascular outcomes data will determine whether enlicitide goes from "promising" to "blockbuster." Merck hasn't announced a specific readout date, but with enrollment complete, the clock is ticking.

If the outcomes trial delivers, Merck won't just have a new cholesterol drug. It'll have a case study in why convenience is the most underrated variable in medicine. The best therapies aren't always the ones with the fanciest mechanism; they're the ones patients actually take.

Sometimes, the revolution comes in a pill bottle.

Astellas Just Killed a Drug No One's Been Able to Make Work

Astellas pulled the plug on its STING inhibitor trial for Sjögren's syndrome before it could even generate human data. The decision says as much about a notoriously undruggable target as it does about where Big Pharma is placing its bets.